Bridgeway Capital Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Bridgeway Capital Management’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-63,300	Closed	-$80.4K	–	1448
2023 Q2	$80.4K	Hold	63,300	–	–	﹤0.01%	1286
2023 Q1	$88.6K	Buy	63,300 +30,000	+90%	+$71.6K	﹤0.01%	1259
2022 Q4	$125K	Sell	33,300 -35,000	-51%	-$128K	﹤0.01%	1186
2022 Q3	$333K	Sell	68,300 -10,000	-13%	-$76.6K	0.01%	1002
2022 Q2	$730K	Hold	78,300	–	–	0.02%	794
2022 Q1	$499K	Hold	78,300	–	–	0.01%	937
2021 Q4	$676K	Buy	+78,300	New	+$782K	0.01%	896

Other funds holding IMPL

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bridgeway Capital Management's IMPL Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2023, closing a stake of 63,300 shares — an estimated $80.4K sold.

Bridgeway Capital Management first reported a position in IMPL in Q4 2021 and held it in 7 quarters. The position peaked at $730K in Q2 2022. 32 funds tracked by Wall St. Rank hold IMPL as of Q3 2023.

Bridgeway Capital Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bridgeway Capital Management sold 63,300 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $80.4K.
Bridgeway Capital Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Bridgeway Capital Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $730K in Q2 2022.
32 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.